Evidence map›Paper›PMID 39660189›Full record

ArticleHeliyon2024

Pyrazole derivatives as antileishmanial agents: Biological evaluation, molecular docking study, DFT analysis and ADME prediction.

Razieh Sabet, Gholamreza Hatam, Leila Emami, Elaheh Ataollahi, Fateme Zare, Leila Zamani, Behnaz Kazemi, Masood Mohabati Jahromi, Sara Sadeghian, Soghra Khabnadideh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Razieh SabetDepartment of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Gholamreza HatamBasic Sciences in infectious diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila EmamiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Elaheh AtaollahiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Fateme ZarePharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila ZamaniPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Behnaz KazemiStudent Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Masood Mohabati JahromiStudent Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Sara SadeghianDepartment of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Soghra KhabnadidehDepartment of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a parasitic disease that is commonly found in tropical and sub-tropical regions. Currently, there is no protective antileishmanial vaccine, and the available clinical drugs have serious side effects. On the other hand, due to the emergence of multidrug-resistant strains of the causative pathogens, the study and design of novel antileishmanial agents is urgently needed. Accordingly, fourteen previously synthesized pyrazole and pyrano [2,3-c] pyrazole derivatives

Indexed as

ADME predictionAntileishmanialDFT analysisMolecular dockingPyrazole

Identifiers

PMID39660189
PMCPMC11629218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.